Stay updated with breaking news from Accessed September. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination
The oral therapy is available through a REMS program.
This evaluation looks at a postdischarge digital engagement (PDDE) program using causal inference methods to examine the impact of PDDE on readmission.
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled...
/PRNewswire/ -- SSM Health, a Catholic, not-for-profit and fully-integrated health system serving the comprehensive needs of communities across the Midwest,...